Search results for " OUTCOMES"

showing 10 items of 356 documents

Absolok® versus Hem-o-Lok® clips for renorrhaphy during partial nephrectomy for parenchymal renal tumors

2020

Background To compare perioperative and functional outcomes associated with renorrhaphy performed with two different types of clips (Absolok® vs. Hem-o-Lok®) in a contemporary series of patients who underwent partial nephrectomy. Methods Patients in whom Absolok® clips were used to perform haemostasis at the level of tumor bed or to block the running sutures during sliding-clip renorrhaphy (study group) were compared with a contemporary control group of patients in whom renorrhaphy was performed with Hem-o-Lok® clips. Both groups received the same surgical technique via an open or robot-assisted approach. Inner renorrhaphy was performed with one or more 3-0 (26 mm needle) monofilament runni…

MaleComplicationsmedicine.medical_treatment030232 urology & nephrologyKidneyNephrectomyPolydioxanonechemistry.chemical_compoundPostoperative Complications0302 clinical medicinePerioperative outcomesRobotic Surgical ProceduresSuture (anatomy)bsolok® clipPartial nephrectomyMedicineProspective StudiesCLIPSIntraoperative ComplicationsProspective cohort studycomputer.programming_languageMiddle AgedSurgical InstrumentsMagnetic Resonance ImagingRenal cell carcinomaKidney NeoplasmsNephrectomyTreatment Outcomesurgical procedures operativeNephrologyPolydioxanone030220 oncology & carcinogenesiscardiovascular systemFemalePositive Surgical MarginAbsolok (R) clips Hem-o-lok (R) clips Renorrhaphy Sliding clip technique Partial nephrectomy Perioperative outcomes Complications Renal cell carcinomaPerioperative outcomeHem-o-Lok® clipmedicine.medical_specialtyKidney CortexUrologyeducationSliding clip technique03 medical and health sciencesHumansRenorrhaphycardiovascular diseasesAgedHemostasisAbsolok (R) clipsSuturesbusiness.industryPerioperativeSurgeryHem-o-lok (R) clipschemistryHemostasisTomography X-Ray ComputedbusinessComplicationcomputerMinerva Urologica e Nefrologica
researchProduct

Liraglutide and cardiovascular outcomes in type 2 diabetes

2016

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjus…

MaleGastrointestinal DiseasesTreatment outcomeClinical BiochemistryMyocardial InfarctionType 2 diabetes030204 cardiovascular system & hematologylaw.inventionMedicine; Endocrinology0302 clinical medicineRandomized controlled trialAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome; Medicine (all)lawCardiovascular DiseaseClinical-trial; Pancreatitis; Therapies; Cancer; Drugs11 Medical and Health SciencesResearch Support Non-U.S. Gov'tMedicine (all)PANCREATITISHazard ratioLEADER Steering CommitteeFollow up studiesGeneral MedicineMiddle AgedAlbiglutideMulticenter StudyStrokeTRIALSTreatment OutcomeCardiovascular DiseasesRandomized Controlled TrialFemaleLife Sciences & BiomedicineCardiovascular outcomesmedicine.drugHumanmedicine.medical_specialtyGastrointestinal DiseaseMEDLINE030209 endocrinology & metabolismLEADER Trial InvestigatorsPlaceboFollow-Up Studie03 medical and health sciencesMedicine General & InternalResearch Support N.I.H. ExtramuralDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicinemedicineJournal ArticleHumansHypoglycemic AgentsAgedGlycemic efficacyScience & TechnologyHypoglycemic AgentLiraglutidebusiness.industrySemaglutideLiraglutidemedicine.diseaseSurgeryDiabetes Mellitus Type 2businessFollow-Up Studies
researchProduct

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countrie…

2015

Summary Background Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013. Methods Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods with some important refinements. Results for incidence of acute disorders and prevalence of chronic disorders are new additions to the analysis. Key improvements include expansion to the cause an…

MaleGerontologyNutrition and DiseaseEpidemiologyyears lived with disability Global burden of disease acute and chronic diseases countriesPrevalenceDiseaseGlobal HealthMedical and Health SciencesConduct disorderOtitis-mediaCost of IllnessResidence CharacteristicsVoeding en ZiekteEpidemiologyPrevalence80 and overGlobal health2.2 Factors relating to the physical environment2.1 Biological and endogenous factorscountriesAetiologyChildAged 80 and overMedicine(all)education.field_of_studyATTENTION-DEFICIT/HYPERACTIVITY DISORDERIncidenceMortality rateIncidence (epidemiology)Pain ResearchNeglected DiseasesAlcohol dependenceGeneral MedicineMiddle AgedGlobal burden of diseaseGlobal Burden of Disease Study 2013 CollaboratorsMental HealthInfectious DiseasesAttention deficit/Hyperactivity disorderBurden of IllnessChild PreschoolAcute DiseaseFemaleLife Sciences & BiomedicineAdultmedicine.medical_specialtyAdolescentGBD 2013Populationacute and chronic diseasesYoung AdultMental-disordersAge DistributionMedicine General & InternalWeightsGeneral & Internal MedicinemedicineHumansLife ScienceDisabled PersonsSex DistributionPreschooleducationDeveloping CountriesVLAGAgedScience & Technologybusiness.industryDeveloped CountriesCutaneous LeishmaniasisInfant NewbornInfantHealth outcomesNewbornmedicine.diseaseComorbidityBrain Disordersyears lived with disabilityGood Health and Well BeingDisease injury incidence prevalence YLDs GBD 2010Chronic DiseaseWounds and Injuriesbusiness2.4 Surveillance and distributionIron-deficiencyDemography
researchProduct

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Preconception genome medicine: current state and future perspectives to improve infertility diagnosis and reproductive and health outcomes based on i…

2021

Abstract BACKGROUND Our genetic code is now readable, writable and hackable. The recent escalation of genome-wide sequencing (GS) applications in population diagnostics will not only enable the assessment of risks of transmitting well-defined monogenic disorders at preconceptional stages (i.e. carrier screening), but also facilitate identification of multifactorial genetic predispositions to sub-lethal pathologies, including those affecting reproductive fitness. Through GS, the acquisition and curation of reproductive-related findings will warrant the expansion of genetic assessment to new areas of genomic prediction of reproductive phenotypes, pharmacogenomics and molecular embryology, fur…

MaleInfertilitymedicine.medical_specialtyPopulationReproductive medicineGenome-wide association studyBioinformaticspolygenic medicinegenetic diagnosis03 medical and health sciences0302 clinical medicinePregnancyreproductive geneticsOutcome Assessment Health CaremedicineGenetic predispositionHumanswhole-exome sequencingProspective StudieseducationIVF/ICSI outcomesExome sequencing030304 developmental biologyReproductive healthGenetic testing0303 health scienceseducation.field_of_study030219 obstetrics & reproductive medicinemedicine.diagnostic_testoocyte and embryo genetic defectsbusiness.industryObstetrics and GynecologyGenomicsmedicine.disease3. Good healthReproductive Medicinewhole-genome sequencingInfertilitygenomic sequencingpreconception carrier screeningFemaleinfertilitybusinessGenome-Wide Association StudyHuman Reproduction Update
researchProduct

Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.

2014

Background: Increased serum uric acid has been considered a cardiovascular risk factor but no study has assessed its relation with hospital mortality or length of stay. On the basis of data obtained from a prospective registry, the prevalence of gout/hyperuricemia and its association with these and other clinical parameters was evaluated in an Italian cohort of elderly patients acutely admitted to internal medicine or geriatric wards. Methods: While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the findin…

MaleKidney DiseaseSettore MED/09 - Medicina InternahyperuricemiaComorbiditieschemistry.chemical_compoundCardiovascular Diseasegout elderlyAllopurinol; Comorbidities; Elderly; Gout; Hyperuricemia; Outcomes; Age Factors; Aged; Aged 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbidity; Female; Gout; Hospital Mortality; Hospitalization; Humans; Hyperuricemia; Kidney Diseases; Length of Stay; Male; Treatment Outcome; Uric Acid; Internal Medicine; Medicine (all)80 and overMedicineAge FactorHyperuricemiaHospital MortalityOutcomeAged 80 and overOUTCOMESMedicine (all)Age FactorsHospitalizationcomorbidityTreatment OutcomeCardiovascular DiseasesAllopurinol; Comorbidities; Elderly; Gout; Hyperuricemia; OutcomesCohortFemaleKidney DiseasesComorbiditieAllopurinol; Comorbidities; Elderly; Gout; Hyperuricemia; Outcomes; Age Factors; Aged; Aged 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbidity; Female; Gout; Hospital Mortality; Hospitalization; Humans; Hyperuricemia; Kidney Diseases; Length of Stay; Male; Treatment Outcome; Uric AcidHumanmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesAllopurinolAllopurinol; Comorbidities; Elderly; Gout; Hyperuricemia; Outcomes; Age Factors; Aged; Aged 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbidity; Female; Gout; Hospital Mortality; Hospitalization; Humans; Hyperuricemia; Kidney Diseases; Length of Stay; Male; Treatment Outcome; Uric Acid; Internal MedicineallopurinolNOgoutGout allopurinol hyperuricemia comorbidities outcomes elderlyInternal medicineInternal MedicineHumansRisk factorIntensive care medicineAdverse effectAgedELDERLYgout allopurinol hyperuricemia comorbidities outcomes elderlybusiness.industrynutritional and metabolic diseasesLength of Staymedicine.diseaseComorbidityGoutUric AcidchemistryChronic DiseaseUric acidbusiness
researchProduct

An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesore…

2018

Introduction: Transanal total mesorectal excision (TaTME) has rapidly emerged as a novel approach for rectal cancer surgery. Safety profiles are still emerging and more comparative data is urgently needed. This study aimed to compare indications and short-term outcomes of TaTME, open, laparoscopic, and robotic TME internationally. Methods: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 audit was performed. Patients undergoing elective total mesorectal excision (TME) for malignancy between 1 January 2017 and 15 March 2017 by any operative approach were included. The primary outcome measure was anastomotic leak. Results: Of 2579 included patients, 76.2% (1966/257…

MaleLaparoscopic surgerymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentOperative TimeAnastomosisMalignancyrectal cancer ; laparoscopic surgery ; TME ; transanal TME ; TaTME ; robotic surgery ; randomized clinical-trial ; short-term outcomes ; laparoscopic-assisted resection ; pathological outcomes ; anastomotic leakage ; initial-experience ; riskNO03 medical and health sciencesPostoperative Complications0302 clinical medicineRobotic Surgical Proceduresrobotic surgerytransanal TMEHumansMedicineRobotic surgeryProspective Studieslaparoscopic surgery; Rectal cancer; robotic surgery; TaTME; TME; transanal TME; GastroenterologyRectal cancerAgedTransanal Endoscopic Surgeryta3126Medical AuditUnivariate analysisProctectomyRectal Neoplasmsbusiness.industryRectumGastroenterologyTMEMargins of ExcisionMiddle Agedmedicine.diseaseTotal mesorectal excisionTaTMElaparoscopic surgerySurgeryTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesisRectal cancer surgeryFemaleLaparoscopy030211 gastroenterology & hepatologybusiness
researchProduct

Observed and relative survival and 5-year outcomes of patients discharged after acute myocardial infarction: the nationwide AMI-PL database.

2020

Background: Long‑term follow‑up data from a large Polish acute myocardial infarction (AMI‑PL) database are still unavailable. Aims: This study aimed to assess the 5‑year outcomes of patients discharged after hospitalization for AMI in Poland in relation to age. Methods: The studywas based on the nationwide AMI‑PL registry including data on the management and long‑term outcomes of all patients admitted to hospitals with AMI (codes I21–I22 according to the International Classification of Diseases and Related Health Problems, 10th Revision [ICD ‑10]), derived from the database of the obligatory healthcare payer in Poland.The current analysis included all patients after AMI who were discharged …

MaleMEDLINEMyocardial InfarctionDischarged alive030204 cardiovascular system & hematologycomputer.software_genre03 medical and health sciences0302 clinical medicineOlder patientsRisk FactorsmedicineHumansIn patientcardiovascular diseasesMyocardial infarctionAgedAged 80 and overnon-ST-segment elevation myocardial infarctionDatabaseRelative survivalbusiness.industryrelative survivalMiddle Agedmedicine.diseasePatient DischargeST-segment elevation myocardial infarctionHospitalizationHeart failurepopulation-based databaseFemalePolandCardiology and Cardiovascular MedicineIndex hospitalizationbusinesscomputerlong-term outcomesKardiologia polska
researchProduct

Safety of primary anastomosis following emergency left sided colorectal resection: an international, multi-centre prospective audit

2018

Introduction: Some evidence suggests that primary anastomosis following left sided colorectal resection in the emergency setting may be safe in selected patients, and confer favourable outcomes to permanent enterostomy. The aim of this study was to compare the major postoperative complication rate in patients undergoing end stoma vs primary anastomosis following emergency left sided colorectal resection. Methods: A pre-planned analysis of the European Society of Coloproctology 2017 audit. Adult patients (> 16 years) who underwent emergency (unplanned, within 24 h of hospital admission) left sided colonic or rectal resection were included. The primary endpoint was the 30-day major complic…

MaleMedical auditTreatment outcomeanastomotic leak030230 surgery0302 clinical medicinePostoperative ComplicationsProspective StudiesMulti centreemergency surgeryProspective cohort studyColectomyMedical AuditProctectomyProctectomy/adverse effectsProspective auditPrimary anastomosisAnastomosis SurgicalGastroenterologyMiddle Agedsurgical complicationsEuropeTreatment Outcomecolon canceranastomotic leak; colon cancer; emergency surgery; gastrointestinal surgery; rectal cancer; Surgery; surgical complications; surgical outcomes; Gastroenterology030220 oncology & carcinogenesisPostoperative Complications/etiologyFemaleColectomy/adverse effectsEmergency Treatment/adverse effectsAdultmedicine.medical_specialtyAdolescentsurgical outcomesurgical outcomesLeft sidedNO03 medical and health sciencesYoung Adultsurgical complicationmedicineHumansgastrointestinal surgeryrectal cancerEmergency TreatmentColorectal resectionAgedta3126Anastomosis Surgical/methodsbusiness.industryGeneral surgerySurgical StomasSurgical Stomas/statistics & numerical dataSettore MED/18 - Chirurgia GeneraleMultivariate AnalysisSurgerybusiness
researchProduct

Maxillary Implant-Supported Overdentures: Mechanical Behavior Comparing Individual Axial and Bar Retention Systems. A Cohort Study of Edentulous Pati…

2020

Background and objectives: To compare the medium- to long-term mechanical behavior of overdentures with two different retention systems: overdentures with Locator&reg

MaleMedicine (General)Dental WearDentistryoverdentureODB++ArticlebarCohort StudiesDental Prosthesis Retentionlocator03 medical and health sciencesR5-9200302 clinical medicinePatient satisfactionSurveys and QuestionnairesmedicineHumansDental Restoration FailureProspective StudiesProspective cohort studyAgedMechanical PhenomenaDental ImplantsEdentulismbusiness.industry030206 dentistrymedicine.diseaseDenture Overlayclinical outcomesTreatment OutcomeScrew looseningPatient SatisfactionAutomotive Engineeringdental implants; overdenture; locator; bar; clinical outcomesFemaleDental Prosthesis Implant-SupportedMouth Edentulousbusiness030217 neurology & neurosurgeryImplant supportedCohort studyFollow-Up StudiesMedicina (Kaunas, Lithuania)
researchProduct